Hyperfine Enrolls First Alzheimer's Patients Receiving Amyloid-Targeting Therapy In CARE PMR Study
Hyperfine Enrolls First Alzheimer's Patients Receiving Amyloid-Targeting Therapy In CARE PMR Study
Hyperfine 在 CARE PMR 研究中招收了首批接受淀粉样蛋白靶向治疗的阿尔茨海默氏症患者
Study will assess the clinical utility and workflow benefits of physicians using images acquired by the Swoop Portable MR Imaging system to identify ARIA events in Alzheimer's patients treated with amyloid-targeting therapy
该研究将使用Swoop便携式磁共振成像系统采集的图像来评估医生的临床效用和工作流程优势，以识别接受淀粉样蛋白靶向疗法治疗的阿尔茨海默氏症患者的ARIA事件
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。